These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23278214)

  • 21. The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim.
    Al-Samkari H; Schifferli A; Gonzalez-Lopez TJ
    Br J Haematol; 2024 Apr; 204(4):1143-1145. PubMed ID: 38319005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
    Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
    Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
    Maan R; de Knegt RJ; Veldt BJ
    Drugs; 2015 Nov; 75(17):1981-92. PubMed ID: 26501978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
    Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
    Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is publication? The case of eltrombopag.
    Benham L; Guo L; Turner R
    Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
    [No Abstract]   [Full Text] [Related]  

  • 26. New thrombopoietin receptor agonists for platelet disorders.
    Homeida S; Ebdon C; Batty P; Jackson B; Kolade S; Bateman C; Peng YY; Stasi R
    Drugs Today (Barc); 2012 Apr; 48(4):293-301. PubMed ID: 22536571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia.
    Álvarez Román MT; Fernández Bello I; Arias-Salgado EG; de Paz R; Jiménez Yuste V; Martín Salces M; Butta NV
    Br J Clin Pharmacol; 2014 Sep; 78(3):674-6. PubMed ID: 24602175
    [No Abstract]   [Full Text] [Related]  

  • 28. Thrombocytopenia: optimizing approaches in cancer patients.
    Piatek C; Akhtari M
    Oncology (Williston Park); 2015 Apr; 29(4):297-8. PubMed ID: 25952494
    [No Abstract]   [Full Text] [Related]  

  • 29. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
    Aguilar C
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):231-6. PubMed ID: 23518832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
    Gudbrandsdottir S; Frederiksen H; Hasselbalch H
    Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
    [No Abstract]   [Full Text] [Related]  

  • 32. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.
    Ruggeri M
    Am J Hematol; 2012 Oct; 87(10):946-7. PubMed ID: 22847498
    [No Abstract]   [Full Text] [Related]  

  • 33. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
    Francesco R
    Eur J Haematol Suppl; 2009 Mar; (71):1-2. PubMed ID: 19200300
    [No Abstract]   [Full Text] [Related]  

  • 34. Immune thrombocytopenia during childhood: new approaches to classification and management.
    Buchanan GR
    J Pediatr; 2014 Sep; 165(3):437-9. PubMed ID: 24973290
    [No Abstract]   [Full Text] [Related]  

  • 35. Thrombopoietic agents.
    Stasi R; Bosworth J; Rhodes E; Shannon MS; Willis F; Gordon-Smith EC
    Blood Rev; 2010; 24(4-5):179-90. PubMed ID: 20493600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moving towards a new era in the management of chronic immune thrombocytopenia.
    Wadenvik H; Olsson B
    Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The new thrombopoietic agenda: impact on leukemias and MDS.
    Bussel JB
    Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
    Piccin A; Amaddii G; Natolino F; Billio A; Cortelazzo S
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912
    [No Abstract]   [Full Text] [Related]  

  • 39. Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim.
    Nakazato T; Ito C; Mihara A; Aisa Y
    Int J Hematol; 2013 Feb; 97(2):291-3. PubMed ID: 23275229
    [No Abstract]   [Full Text] [Related]  

  • 40. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
    Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.